1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow 1.0% IP-001 for injection: new trials by email Literature Review of 1.0% IP-001 for injection trials Research Report on 1.0% IP-001 for injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone 1.0% IP-001 for injection, Surgical Resection and Local Ablation, Local Ablation Alone - Hepatocellular Carcinoma | Phase 2 | Recruiting | Robert C. Martin | 315 | 2024-07-24 | 2026-09-04 |
| Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS 1.0% IP-001 for Injection - Metastatic Solid Tumor, Colon Cancer | Phase 1 / Phase 2 | Active not recruiting | Immunophotonics, Inc. | 42 | 2022-11-29 | 2025-01-08 |
Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Sarcoma (1)
Immunophotonics, Inc. (1) · Robert C. Martin (1)
United States (2) · France (1) · Germany (1) · Switzerland (1) · United Kingdom (1)
Diane Beatty, PhD (1) · Markus Jorger, MD (1) · Robert CG Martin, MD, PhD (1)